<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114096</url>
  </required_header>
  <id_info>
    <org_study_id>3764</org_study_id>
    <nct_id>NCT05114096</nct_id>
  </id_info>
  <brief_title>Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)</brief_title>
  <acronym>SNACS</acronym>
  <official_title>Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm&#xD;
      infants, such as respiratory distress syndrome.&#xD;
&#xD;
      The standard of care for pregnant people at risk of preterm birth includes 2 doses of&#xD;
      Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung&#xD;
      maturity.&#xD;
&#xD;
      The investigators plan to conduct a randomized controlled trial to determine whether half the&#xD;
      usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the&#xD;
      standard double doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm infants are at risk of mortality and morbidity. Antenatal corticosteroids (ACS)&#xD;
      reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome.&#xD;
&#xD;
      The standard of care for pregnant people at risk of preterm birth includes 2 doses of&#xD;
      Celestone to accelerate fetal lung maturity (total 24 mg in Canada, 22.8 mg in Australia).&#xD;
      There are no published clinical trial data on the benefits or risks of a single dose of&#xD;
      antenatal corticosteroid vs. standard double doses (Ninan et al JOGC 2020).&#xD;
&#xD;
      Pregnant people at 22 weeks and 0 days to &lt; 34 weeks and 6 days' gestation at risk of preterm&#xD;
      birth with a singleton or twin gestation who have received the first dose of Celestone and&#xD;
      consented to the trial will be randomized to receive approximately 24 hours later either an&#xD;
      experimental placebo injection (of normal saline) or the standard double dose of Celestone to&#xD;
      determine whether the intervention is non-inferior for the primary outcome of a composite of&#xD;
      perinatal mortality or substantial morbidity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, blinded, pragmatic, 2 arm non-inferiority RCT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perinatal Mortality or Substantial Neonatal Morbidity</measure>
    <time_frame>approximately 1 month</time_frame>
    <description>Fetal death post-randomization or in hospital neonatal death OR =&gt; 1 of respiratory morbidity (requiring surfactant &lt;48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual components of the above composite primary outcome</measure>
    <time_frame>approximately 1 month</time_frame>
    <description>Fetal death post-randomization or in hospital neonatal death OR =&gt; 1 of respiratory morbidity (requiring surfactant &lt;48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or neurosensory/developmental impairment at 24 months</measure>
    <time_frame>approximately 24 months</time_frame>
    <description>Death or neurosensory/developmental impairment at 24 months (+/- 6 months; accounting for gestation at birth), mood (anxiety/depression), behavior (aggression), etc as assessed by:&#xD;
Ages and Stages Questionnaire-3 (ASQ), which has 5 domains:&#xD;
i) Communication, ii) Gross Motor, iii) Fine Motor, iv) Problem Solving, v) Personal-Social and vi) Overall Development (including vision and hearing).&#xD;
Child Behavior Checklist: 4 subscales i) Anxious/Depressed, ii) Aggression, iii) Withdrawn &amp; iv) Hyperactivity subscales.&#xD;
Physician diagnosis of cerebral palsy (parent report).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of babies who received intubation and duration of invasive mechanical ventilation</measure>
    <time_frame>approximately up to first 6 months of life</time_frame>
    <description>Number of babies who received intubation and duration of invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support</measure>
    <time_frame>approximately up to first 6 months of life</time_frame>
    <description>Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with meconium aspiration syndrome</measure>
    <time_frame>approximately 1 month</time_frame>
    <description>Number of babies with meconium aspiration syndrome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with persistent pulmonary hypertension of the newborn</measure>
    <time_frame>approximately 1 month</time_frame>
    <description>Number of babies with persistent pulmonary hypertension of the newborn.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with hypoglycemia</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of babies with hypoglycemia (low plasma glucose &lt; 2.6 mmol/L between 30 minutes and 48 hours of life)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with neonatal sepsis</measure>
    <time_frame>7 days</time_frame>
    <description>Number of babies with neonatal sepsis within 7 days of birth, defined as a positive (bacterial, viral or fungal): blood culture or cerebrospinal fluid culture (or gram stain) or urine culture by sterile collection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with severe retinopathy of prematurity needing treatment</measure>
    <time_frame>approximately first few months of life</time_frame>
    <description>Number of babies with severe retinopathy of prematurity defined as requiring vascular endothelial growth factor (VEGF) or laser or cryotherapy per the local guidelines</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)</measure>
    <time_frame>up to 12 weeks after birth</time_frame>
    <description>Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry at birth and at 24 months corrected age</measure>
    <time_frame>at birth and at 24 months corrected age</time_frame>
    <description>Weight (in grams), length (in centimeters), and head circumference (in centimeters) for birth week as ACS can impact growth</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with severe late brain injury</measure>
    <time_frame>up to 20 weeks postnatal</time_frame>
    <description>Periventricular leukomalacia [PVL], i.e. cystic changes in white matter or porencephalic cysts or white matter changes diagnosed by ultrasound or MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with chronic lung disease</measure>
    <time_frame>approximately up to first 6 months of life</time_frame>
    <description>Late respiratory morbidity, bronchopulmonary dysplasia (BPD), defined as requiring respiratory support or supplemental oxygen &gt; 36 completed weeks' corrected gestation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Apgar score and cord blood pH</measure>
    <time_frame>approximately at birth</time_frame>
    <description>Apgar score (at 1 and 5 min) and lowest cord blood pH, regardless of whether arterial or venous.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay in an intensive care setting</measure>
    <time_frame>approximately up to first 6 months of life</time_frame>
    <description>Length of stay in an intensive care setting such as the neonatal intensive care unit (NICU).</description>
  </other_outcome>
  <other_outcome>
    <measure>Use of postnatal corticosteroids</measure>
    <time_frame>up to 20 weeks postnatal</time_frame>
    <description>Use of systemic (intravenous or oral) postnatal corticosteroids and type (e.g. hydrocortisone, dexamethasone).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with longterm health care outcomes</measure>
    <time_frame>approximately 5 -10 years</time_frame>
    <description>Number of babies with reported longterm health care outcomes after initial hospital, such as hospitalizations, and other health care use.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of babies with longterm education outcomes</measure>
    <time_frame>approximately 5 -10 years</time_frame>
    <description>Number of babies with reported longterm education or non-health data outcomes, collected through database linkage where possible.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3254</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Premature Birth</condition>
  <condition>Complication of Prematurity</condition>
  <condition>Obstetric Labor, Premature</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Single-Dose Celestone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental &quot;Single-Dose&quot; arm will receive a similar appearing placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Dose Celestone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the &quot;Double-Dose&quot; arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celestone + placebo</intervention_name>
    <description>After the first intramuscular injection of Celestone, participants randomized to the &quot;Placebo Comparator&quot; group will receive 1 intramuscular injection of placebo.</description>
    <arm_group_label>Single-Dose Celestone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celestone + Celestone</intervention_name>
    <description>After the first intramuscular injection of Celestone, participants randomized to the &quot;Active Comparator&quot; group will receive 1 intramuscular injection of Celestone.</description>
    <arm_group_label>Double-Dose Celestone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or&#xD;
             twins between 22 weeks and 0 days and &lt;34 weeks and 6 days gestation who have received&#xD;
             only a single dose of Celestone within 24 hours&#xD;
&#xD;
          2. All fetuses must be without compromise as per ultrasound or fetal heart rate monitor&#xD;
             (so that waiting 24 hours for the study medication is acceptable).&#xD;
&#xD;
          3. Capable of giving informed, written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to corticosteroids&#xD;
&#xD;
          2. Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus,&#xD;
             severe asthma, Covid, etc).&#xD;
&#xD;
          3. Previous participation in this trial (in a previous pregnancy)&#xD;
&#xD;
          4. Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal&#xD;
             congenital/chromosomal abnormality)&#xD;
&#xD;
          5. Demise of one or more fetuses after 14 weeks and 0 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah D McDonald, MD,MSc,FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kellie Murphy, MD,MSc,FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah D McDonald, MD,MSc,FRCSC</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>26622</phone_ext>
    <email>mcdonals@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Hospital for Women</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of New South Wales, St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sydney; Westmead Institute for Maternal Fetal Medicine, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Darwin Hospital</name>
      <address>
        <city>Tiwi</city>
        <state>Northern Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Queensland and Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Centre for Maternal Fetal Medicine</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Queensland; Mater Research Institute/University of Queensland</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital and Health Services</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Adelaide; Women's &amp; Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorabbin Hospital, Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Melbourne; Mercy Hospital for Women</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Women's Hospital; University of Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Melbourne; Joan Kirner Women's &amp; Children's Sunshine Hospital</name>
      <address>
        <city>Saint Albans</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Cumming School of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Health Services; University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia; BC Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba; St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Everett Chalmers Regional Hospital</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital, Horizon Health Network</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial University, Eastern Health</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University, Kingston General Hospital Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University; London Health Sciences Centre, Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa; The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University, McGill University Health Center, Royal Victoria Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis Jewish General Hospital; McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Laval, Centre de recherche du CHU de Québec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(CIUSSS de l'Estrie-CHUS); Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan, Regina General Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.jogc.2020.02.127</url>
    <description>Neonatal and Maternal Outcomes of Lower Versus Standard Doses of Antenatal Corticosteroids for Women at Risk of Preterm Delivery: A Systematic Review of Randomized Controlled Trials</description>
  </link>
  <reference>
    <citation>Ninan K, Morfaw F, Murphy KE, Beyene J, McDonald SD. Neonatal and Maternal Outcomes of Lower Versus Standard Doses of Antenatal Corticosteroids for Women at Risk of Preterm Delivery: A Systematic Review of Randomized Controlled Trials. J Obstet Gynaecol Can. 2021 Jan;43(1):74-81. doi: 10.1016/j.jogc.2020.02.127. Epub 2020 Mar 26. Review.</citation>
    <PMID>32660867</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature birth</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Obstetric labour</keyword>
  <keyword>Betamethasone</keyword>
  <keyword>Betamethasone Valerate</keyword>
  <keyword>Betamethasone-17,21-dipropionate</keyword>
  <keyword>Betamethasone benzoate</keyword>
  <keyword>Betamethasone sodium phosphate</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes and Hormone Antagonists</keyword>
  <keyword>Physiological Effect of Drugs</keyword>
  <keyword>Anti-Asthmatic Agents</keyword>
  <keyword>Respiratory System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>An IPD is planned with trial leaders of another half dose Celestone study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

